Introduction

Microvesicles(MVs,also known as microparticles)were first described in 1967[1].At that time,MVs were thought as‘‘dust” from platelets.In the past decades,increasing evidence indicates the importance of MVs in the pathogenesis of various human diseases.MVs are small membrane fragments shed from almost all eukaryotic cells during activation or apoptosis[2–4].MVs have been detected in blood,urine,synovial fluid,and many other body fluids from patients with various diseases[5].Moreover,elevated MV concentrations have already been observed in atherosclerotic plaques,tumor tissue,and other solid tissue/organs in disease states[6].

新生儿在护理期间,上述我们也提及,即护理人员所面对、服务的是无法表达自我情感的新生儿,加上新生儿作为家庭中“希望”、获得无尽疼爱的角色,因此护理期间仍需以家属间的沟通为主,若存在护理过程稍有差池,便可爆发医患冲突,形成纠纷。因此,应加强对家属与护理人员的教育,确保护理人员在展开护理工作期间除了具备认真、积极的工作态度外,应采取良好沟通与患者完成意见交流;在家属方面应强调积极、主动配合临床医护人员的工作,加上健康宣教以期增强医患间的关系和谐,实现互相理解、信任、包容的和谐关系,最终减少紧张医患关系造成的紧张氛围,化解潜在的冲突因素。

Growing evidence[7–9]demonstrates that MVs can harbor not only membrane proteins and lipids from the cell surface,but also nucleic acids(DNA and RNA)including mRNAs,microRNAs(miRNAs),small-interfering RNAs(siRNAs),and long non-coding RNAs(lncRNAs)from the intracellular environment.Because they harbor various components from their parental cells,MVs could perform various functions in intercellular communication,signal transduction,and immune regulation.Therefore,certain specific MVs with some pathological features might be utilized to identify or detect pathological conditions during the development of human diseases.Several studies have indicated that MVs released from blood cells could have potential diagnostic roles in acute coronary syndrome(ACS)[10],ST-elevation myocardial infarction(MI)[11,12],cardiac remodeling[13],type 2 diabetic mellitus[14,15],diabetic retinopathy[16,17],as well as other cardiometabolic diseases.In this review,we provide an overview on the advances of MV-related investigations in cardiometabolic diseases and illustrate the potential roles of MVs as biomarkers or therapeutic targets.

Characteristics of MVs

MVs(0.1–1 μm in diameter),which are budded as small membrane protrusions around a small portion of cytoplasm,could be released from cell membrane surface to extracellular milieu through calpain activation,calcium influx,and cytoskeleton reorganization [18].In contrast,exosomes are smaller(30–100 nm)and originated from endosomal vesicles through secretion from intracellular luminal space[2].The extensive plasma membrane budding during apoptotic blebbing forms MVs and apoptotic bodies[19],which have much larger sizes(1–5 μm).Many studies in the literature have indicated differential molecular expression between MVs and exosomes[20].However,the new term,extracellular vesicle(EV),which comprises exosome,MV,and apoptotic body(Figure 1),has been widely accepted in the field[19–22].

The most important feature of MVs is heterogeneity.MVs induced by different stimuli could carry different components even if they are from the same cell type.In addition,when different cell types are treated with the same stimulus,the released MVs may also carry different components because of the intrinsic dissimilarity[23].In fact,some MVs may harbor specific biomarkers from cell surface of their parental cells.Therefore,detecting specific biomarkers on MVs could be used to identify their cellular origins.

In normal cells,anionic phospholipids,such as phosphatidylserine(PS),are only located in the inner leaflet of cell membrane bilayer[24].During cell apoptosis or release of MVs,PS is shifted to the outer leaflet of the bilayer membrane,and then released with MVs from apoptotic or activated cells[25].The triggers for the release of cellular MVs include many physical and chemical stimuli,such as cytokines,cholesterol enrichment[26],thrombin,cytotoxic chemotherapy [27],tobacco smoke exposure[28–30],hypoxia[31],shear stress[32],and many more[19].Moreover,many of these triggers,e.g.,hypertension,atherosclerosis,MI,diabetes,obesity,and hypercholesteremia,are involved in cardiovascular and metabolic diseases[19,23].Thus,the release of MVs could reflect the pathological conditions of the disease development.By harboring various components from their parental cells of different origins,MVs,therefore,may bridge the connection between distant cells and play a novel role in intercellular communication during the development of human diseases[33].

MVs as intercellular messengers

When MVs are associated with specific receptors,the recipient cells could be activated by endocytosis pathway or directly diffuse to the plasma membrane[19].Therefore,the bioactive components bearing on MVs may participate and mediate thrombosis,endothelial dysfunction,or angiogenesis in the pathological process of cardiometabolic diseases(Figure 2).Due to the exposure of PS and tissue factor(TF),MVs may induce intercellular communication and crosstalk in vascular inflammation and venousthromboembolism[19,34].Ourrecent published work hasshown thatMVscarry active disintegrin and metalloproteinase domain-containing proteins(ADAMs),in the intraluminal thrombus,close to the aneurysmal wall of abdominal aortic aneurysm(AAA),therefore possibly contributing to the degradation of extracellular matrix of the aortic wall and the development of human AAA[35].Another work from our group indicates that the nuclear high mobility group box-1 protein(HMGB1)may redistribute from the nucleus to the cytoplasm and plasma membrane ofmacrophages,and then release to the extracellular milieu with membrane MVs,after exposure to tobacco smoke extract(TSE)[30].Importantly,these HMGB1-associated MVs may mediate sterile inflammation of various metabolic and autoimmune diseases[19,30].In addition,platelet and tumor cell-derived MVs could play a vital role in angiogenesis by transferring a series of proangiogenic factors,including growth factors such as vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF)and platelet-derived growth factor(PDGF),chemokine receptors such as C–C chemokine receptor type 5(CCR5),C-X-C chemokine receptor type 4(CXCR4),and matrix metalloproteinases(MMPs)such as MMP2 and MMP9,which contribute to vessel repair,sprouting,and invasiveness[36,37].

In addition to proteins and lipids,extracellular MVs may also carry DNA,mRNAs,miRNAs,lncRNAs,and other genomic structures[19].Therefore,MVs may contribute to the transient or persistent phenotypic changes due to their function of transferring genetic information to recipient cells[38–40].Extracellular miRNAs packaged by MVs have been shown to play an important role in inflammatory,cardiovascular,and metabolic diseases[41–43].For instance,in vivo intravascular injection of endothelial cell-derived MVs(EMVs)containing miR-126 can accelerate re-endothelialization in carotid arteries after the mice were subjected to the injury from electric denudation[44].Let-7 miRNA family was secreted with MVs in metastatic gastric cancer,which may facilitate oncogenesis or metastasis[40].In addition,Murakami et al.[45]collected human urinary EMVs from healthy donors,and quantified some kidney-specific mRNAs,including PDCN and NPHN(involved in glomerular filtration),SLC12A1(involved in tubular absorption),ALB and UMOD(involved in tubular secretion),and AQP2(involved in collecting duct water absorption).Yang et al.[46]confirmed that MVs were

Arterial hypertension,which is a vital risk factor for atherosclerosis,stroke,and CAD,has been regard as the consequence of endothelial dysfunction in early stage of these diseases.Preston et al.[132]have demonstrated that both EMVs and PMVs are significantly elevated in severe hypertension,while EMVs were associated with the level of both systolic and diastolic blood pressures.As the final target of the renin angiotensin system,angiotensin II could accelerate the release of prothrombotic MVs from mononuclear cells in patients with arterial hypertension[133].Hsu et al.[134]report that elevated EMVs may serve as biomarker to assess the impaired kidney functions since the increased EMVs have been associated with the decrease in glomerular filtration rate in patients.

2) 商铺媒介广告发布。商圈APP提供商铺个性化的宣传和发布功能，弥补因场地问题引起广告位不足的缺陷。对商铺的宣传广告进行定时发布、定时撤销,同时允许商家自行根据模板设计广告，通过审核之后完成商铺产品的推广。

Microvesicles as biomarkers of cardiovascular and metabolic diseases

In the past decades,gigantic efforts have been made to identify new biomarkers for detecting the disease risk and monitoring the therapeutic efficacy for the treatment of cardiovascular and metabolic diseases.Among a number of candidates,cellular MVs could serve as biomarkers to provide a comprehensive assessment of certain cardiometabolic diseases(Table 1),although the specificity of MVs is still uncertain.

VarioustypesofMVsare released into the extracellularenvironmentin the human body,carrying membrane,cytosolic,and nuclear components from their parental/donor cells.It is believed that the detectable biomarkers carried or expressed by MVs may be involved in reprogramming of the target/recipient cells[47].These MVs are easily obtained from body fluids including blood,therefore they can serve as biomarkers in various cardiometabolic diseases[48].Some studies have shown that the levels of platelet-derived MVs(PMVs)and EMVs are increased in circulation in patients with stable coronary artery disease(CAD)[49–51],while the levels of leukocyte-derived MVs(LMVs)in the blood are associated with unstable plaques[52].

However,there are still great challenges for the development of reliable and efficient methods for the routine analysis of MVs or exosomes.The mechanism of transporting genetic contents from the cellular context into the MVs remains unclear.Therefore,it is not easy to select the optimal measure to analyze MVs in liquid biopsy.Moreover,the quantitative analysis of the genetic contents in MVs from biofluids could not be achieved yet due to the low abundance of MVs in biofluids and potential loss during sample processing.Another issue is that the components of biofluid could be affected by food intake,medications,or other physiologic and pathological factors.Thus,the optimal method of biofluid collection would be likely to depend on intended assays and biomarkers.In conclusion,there are difficulties in applying MVs in clinical practice for the time being.

Numerous studies have reported that plasma EMVs can serve as a novel biomarker of endothelial dysfunction,suggesting their diagnostic value in several cardiometabolic diseases,such as CAD[60],ischemic left ventricular dysfunction[61],obesity[62],type 2 diabetes mellitus(T2DM)[63],and chronic renal failure[64].Schiro et al.[65]reported that patients with symptomatic carotid artery disease have signif icantly elevated plasma levels of endothelial membrane microparticles(EMPs).Compared to the CAD patients with low risk lesions and no thrombi,plasma levels of EMVs are dramatically increased in patients with high risk lesions with multiple irregular thrombi[66].In patients with systemic lupus erythematosus(SLE),the elevated EMPs levels in blood are associated with endothelial dysfunction.Moreover,immunosuppressive therapy for SLE patients can significantly reduce the circulating EMPs’levels[67].

LMVs are considered to carry many kinds of bioactive proteins,including interleukine-1 beta(IL-1β),intercellular cell adhesion molecule-1(ICAM-1),and MMPs.LMVs may be involved in leukocyte activation and monocyte migration to endothelial cells[68–70].Furthermore,these extracellular vesicles may play an important role in both atherogenesis and plaque instability[19].Our previous work has shown that monocyte/macrophage cell-derived MVs that are released after TSE treatment or cholesterol enrichment may serve as novel carriers of danger signals[30,71],novel contributors to atherosclerosis,immunologic and thrombotic responses in vivo[29,30,35,71].MVs released from macrophages exposed to TSE contain transmembrane protease MMP14 with gelatinolytic and collagenolytic activities[29].In the intraluminal thrombus of aorta of the patients with AAA,MV-associated active a disintegrin and metalloproteases(ADAMs)may contribute to the degradation of extracellular matrix of the aortic wall during the development of AAA[34].Furlan-Freguia et al.demonstrated that P2X purinoceptor 7(P2X7R)stimulated by ATP can increase the release of MVs from macrophages and these MVs may be involved in procoagulation status of carotid artery thrombosis model[72].

In sickle cell disease,erythrocyte-derived MVs aggravate the loss of sickled cells and promote activation of the coagulation cascade[73,74].In addition,the presence of genetic components(for example,miRNAs,siRNAs,and lncRNAs)in MVs from blood or other biological fluids suggests that MVs could be considered as novel biomarkers for pathological processes.Therefore,MVs in blood or other body fluids could be exploited in liquid biopsy for diagnostic and prognostic goals[75].

“互联网+”时代的到来，跨境电商迅速崛起，标志着全球贸易进入了线上线下深度融合，一体化发展的新时代。高职院校商务英语专业需在人才培养方面与时俱进，积极向跨境电商方向转型，调整专业培养目标，改革课程体系，加快专业师资队伍建设，提升实践教学水平，为企业培养紧缺人才，只有如此，高职商务英语专业才能找准自身定位，跳出自身发展困境，探索出一条专业发展的新路。

Liquid biopsy has attracted growing attention because the application of this skill has been generalized in detecting tumors,assessing disease prognosis,monitoring systemic treatment methods,and identifying precise therapeutic targets[76].Currently,three approaches are used in liquid biopsy,including circulating tumor cells,cell-free DNA,and exosomes[77].Both MVs and exosomes derived from the biofluids of patients could harbor disease-specific mRNAs,miRNAs,proteins,or lipids,thus providing a good source for liquid biopsy in tumor and cardiometabolic diseases.An invasive endomyocardial biopsy has been used to predict the diagnosis of myocarditis by combining immunohistochemistry together with histology[78].Recent studies[7,79]have shown that MVs from cardiomyocytes may carry informative cargoes,containing proteins,peptides,several classes of RNA molecules,and sometimes DNA,for similar purpose,therefore they could be exploited for liquid biopsy,prognosis,or therapeutic targets of cardiac diseases.

Several clinical studies have indicated that MVs could serve as novel therapeutic targets in some conventional treatments for CAD.For instance,the amounts of procoagulant MVs are significantly reduced in the patients with acute MI treated by percutaneous transluminal coronary angioplasty(PTCA)and GP IIb/IIIa antagonists[49].Treatment with n-3 fatty acids in MI patients leads to the decreased levels of PMVs and MMVs,which may possibly explain the mechanisms underlying the anti-inflammatory and anti-thrombotic functions of the treatment in clinical practice[101].

3.创新高校教学管理方式，理论知识与实践教育相结合。鼓励大学生创业不仅需要书本知识，还需要投身到实践中去。目前许多高校都设立大学生孵化中心，为学生创业实践提供场地，但许多高校的孵化中心流于形式，并没有很好利用在大学生创业实践中，而是用于许多商业用途。大学生创业创新的培养需要不断在实践当中去学习和提高，需要不断引入新技术。高校要提供全方位、多领域的创业实践平台为大学生使用。大学生是拥有集学历、技术、知识文化于一身的高尖端人才，大学生创业要不断多元化。高校在教师培训方面也要不断强化，加强对教师专业化的培训，老师带领学生一起走出课堂，走出课本，用实际行动促进“好创意”的诞生。

PMVs are the main culprit in the development of thrombosis,since they provide multiple glycoproteins(GPs)and phospholipids,including PS,GP IIb/IIIa,and P-selectin.Accumulating studies suggest that PMVs may also contribute to platelet activation during atherothrombosis[53–55].Wang et al.[56]have shown that PMV–CD36 complex could activate mitogen-activated protein kinase signaling pathway,mediate oxidative stress and platelet activation in cardiovascular disease(CVD).Furthermore,PMVs might be associated with certain coagulation factors,such as factor Va,VIIIa,and IXa,on the phospholipid membrane surface and result in platelet activation and thrombosis[57].As expected,circulating PMVs in diabetic patients could be significantly decreased by the antiplatelet drugs taken[58,59].

MVs in cardiometabolic diseases

MVs and atherothrombotic disease

Atherosclerosis is caused by the subendothelial retention,or trapping,of cholesterol-rich,apolipoprotein B (apoB)-containing lipoproteins,particularly low-density lipoprotein(LDL)and remnants.These retained lipoproteins become modified,e.g.,by local enzymes,and provoke a series of strikingly maladaptive responses that include chronic sterile inflammation.Rupture-prone plaques comprise depositions of cholesterol and inflammatory cells with only a thin fibrous cap over the atherosclerotic lesion[80,81].

MVs are considered to be pro-thrombotic since they carry TF,which triggers the initiation of extrinsic coagulation pathway,and PS,which provides phospholipid surface for coagulation factors Va,VIII,IXa,and IIa during coagulation process[82].Our previous studies indicate that simulation of human acute monocytic leukemia cell line(THP-1 cells)or primary human monocyte-derived macrophages with cholesterol loading or TSE exposure causes the release of TF-positive MVs, which exhibits potent procoagulant activities[26,28,72].In addition to TF and PS,MVs may be associated with other bioactive components,such as P-selectin[83],GP IIb/IIIa[84],protein disulfide isomerase[85],as well as factor VIII and Va[86],all of which might be involved in atherothrombotic diseases.

In clinical studies,MVs could induce the release of IL-6 and monocyte chemoattractant protein-1(MCP-1),and the expression of TF in healthy volunteers[87,88].Keuren et al.[89]have found that the exposure to stress-induced PMVs could increase the secretion of IL-8,tumor necrosis factor-α (TNF-α),and IL-1β from monocytes and endothelial cells.All of these cytokines could induce upregulation of leukocyte-endothelial adhesion molecules,and cause the adhesion of monocytes to endothelium and the subsequent subendothelial transmigration,thus contributing to atherogenesis.Moreover,the increased apoptosis or activation of leukocytes,smooth muscle cells,and endothelial cells result in the accumulation of MVs[90].Suades et al.[91]demonstrate the association between circulating MVs and atherosclerosis in patients with familial hypercholesterolaemia(FH).The FH patients had higher overall circulating MV levels,especially EMVs.Furthermore,the levels of CD45+/CD3+-MVs were elevated in FH patients with subclinical atherosclerotic plaques.Notably,elevated oxygenized low density lipoprotein in FH may induce the release of MVs derived from monocytes[92].Therefore,the presence of a considerable amount of pro-inflammatory MVs in vascular wall may be important for the development and progression of atherosclerotic plaque.

MVs and coronary artery disease

CAD,featured by stenosis or obstruction of coronary artery,leads to the occurrence of myocardial ischemia or even infarction.Increasing clinical evidence has indicated the link between elevated plasma MVs and the risk or incidence of CAD[7,21,23].Moreover,MVs may play an important role in the development of atherothrombotic CAD through their proinflammatory effects,including atherogenesis,induction of endothelial dysfunction,thrombus formation,and plaque rupture[7,21,23].

Recent studies demonstrated that patients with ACS have higher levels of PMVs as compared to patients with stable angina or other non-CAD controls[93].Bernal-Mizrachi et al.[51]have shown the elevated EMVs levels in patients with CAD as compared to healthy controls.Moreover,elevated levels of MVs have been observed in patients with MI as compared to those with unstable angina[51].A correlation has also been reported between PMVs and thromboxane B2,endothelin-1,platelet-activating factor in patients with coronary intermediate lesions[94].In addition,there is an increase in PMVs after the application of intravenous ultrasound/fractional flow reserve,suggesting that PMVs may be involved in platelet activation and endothelial dysfunction.Furthermore,Jayachandran et al.[95]find that the increased PMVs are associated with early stage of coronary artery calcification in menopausal women with CAD.By isolating coronary artery endothelial cells(CAECs)and collecting EMVs directly from coronary artery plaque[96],Radecke et al.find increased expression of vascular cell adhesion protein 1(VCAM-1)on CAECs and EMVs in the patients with MI.Other studies have suggested that presence of regulated upon activation normal T-cell expressed and secreted(RANTES),a proinflammatory member of the C–C chemokine family,may have an important role when evaluating restenosis after percutaneous coronary intervention(PCI).However,PMVs are associated with the levels of RANTES,suggesting that it may be useful for monitoring atherosclerotic events after PCI[97,98].However,MVs are not necessarily detrimental in the development of CAD.EMVs may have anticoagulant properties by carrying thrombomodulin and endothelial protein C receptor[99,100].

储存4个月后，低温避光的热榨与冷榨汉麻籽油颜色、透明度基本不变，设为对照油脂；室温避光下热榨油外观颜色为深墨绿色，油脂透明，冷榨油外观颜色为浅墨绿色，油脂透明，瓶口有部分油脂颜色发生变化；烘箱环境颜色变化不明显，但有微浊现象，底部也有少量沉淀黏稠油脂；室内环境油脂颜色变浅，均有微浊现象，底部也有少量沉淀黏稠油脂；室外环境油脂颜色变浅发亮，底部均有少量沉淀现象，底部也有少量沉淀黏稠油脂。

Microvesicles and heart failure

Heart failure(HF)results from the cardiac remodeling post MI and can be caused by stress through various adverse conditions,like CAD,atrial fibrillation,elevated blood pressure,and valvular heart disease.Cardiac remodeling leads to compensatory hypertrophy of cardiomyocytes and myocardial fibrosis.

Both in vitro and in vivo experiments have shown that procoagulant MVs may trigger and propagate coagulation in DM.The positive feedback loop of thrombin,platelet,and MVs may represent new mechanisms underlying hypercoagulability in diabetes[117].Cimmino et al.[118]have indicated that MVs associated with procoagulant TF are significantly elevated in patients with DM,suggesting that MVs may serve as a novel biomarker for coagulation.EMVs induced by high glucose stimulation could aggravate endothelial dysfunction,cause macrophage transmigration,and induce the expression of adhesion molecules[119].The underlying mechanism may be associated with increased nicotinamide adenine dinucleotide phosphate(NADP)oxidase activity and higher reactive oxygen species(ROS)levels[120].

Deep Learning是机器学习的一个分支。机器学习（Machine Learning）是专门研究计算机怎样模拟或实现人类的学习行为，以获取新的知识或技能，重新组织已有的知识结构使之不断改善自身的性能的学科。

Lately,Zhang et al.[110]analyzed the extracellular vesicle protein levels in a study involving 404 patients who were diagnosed as HF at the emergency room.The protein levels of cystatin C,serpinG1,and CD14 in extracellular vesicles were significantly higher in HF patients as compared to those in controls.In this study,the patients with HF were classified into two groups,that is,HF with reduced ejection fraction(HFREF)and HF with preserved ejection fraction(HFPEF).They found that the levels of serpin G1 and CD14 were elevated in patients with HFREF,whereas the patients with HFPEF had higher serpin F2 and lower serpin G1 levels[110].Moreover,the levels of serpin G1 in extracellular vesicles were significantly different between HF patients with and without MI history.As a result,they concluded that extracellular vesicle levels of CD14,serpin G1,and serpin F2 are associated with the occurrence of HF in patients suspected for acute HF.

Microvesicles and diabetes mellitus

Diabetes mellitus(DM),particularly T2DM is associated with accelerated development of atherosclerotic disease,which leads to increased morbidity and cardiovascular complications.Type 1 diabetes mellitus(T1DM)patients have been found to possess a higher number of EMVs,PMVs,and total PS-positive MVs[14].However,the increase in total MVs seems not statistically significant in T2DM patients as compared to the age-matched controls.In contrast,the levels of PS-positive,erythrocyte-derived MVs were significantly elevated in T2DM patients[111].Furthermore,the elevated MVs from T1DM patients are associated with procoagulant activity,suggesting their correlation with impaired glucose tolerance and homeostasis[112].However,MVs associated with dipeptidyl peptidase IV(DPP-IV)in T2DM patients may be involved in glucose metabolism,because DPP-IV can positively affect the incretin degradation [113].The positive correlation between MV-associated DPP-IV and the urinary albumin/creatinine ratio in patients with diabetic nepheropathy has also been demonstrated in other studies[114–116].

Analysis of endothelial dysfunction could be useful for assessment of cardiovascular complications of HF,given the growing evidence supporting the occurrence of endothelial dysfunction in HF[102,103].Nozaki et al.[104]recruited 169 consecutive HF patients for detection of the circulating EMV levels,and demonstrated that elevated EMVs could provide valuable information for future cardiovascular events in patients with HF status.In addition,circulating MVs in plasma can be quantified serving as biomarkers for diagnosis and therapeutic monitoring in peripartum cardiomyopathy[105]or Churg-Strauss Syndrome-induced cardiomyopathy[106].Furthermore,the decreased circulating MVs after immunoadsorption treatment may be related to the improvement of endothelial function in patients with chronic dilative cardiomyopathy[107].

2016年，苏为科教授课题组［10］通过多组分一锅法制备得到多种新型二氢吡喃并［2，3-c］吡唑类衍生物，本研究对其中第36号衍生物（后称36号化合物，结构式见图2）的体外抑瘤作用和可能的作用机制进行探讨，旨在为进一步的结构优化和体内抗肿瘤活性研究等提供实验依据。

In addition to coagulation and endothelial dysfunction,numerous studies have also illustrated that MVs may be involved in angiogenesis in DM.For instance,Tsimerman et al.[17]have reported that MVs may play important roles in angiogenesis and skin healing in patients with DM.When MVs were incubated with human umbilical vein endothelial cells(HUVECs),angiogenesis could be induced,resulting in the formation of stable and branched endothelial networks.Ettelaie et al.[121]have also demonstrated that the TF-associated MVs could be induced by glucose or advanced glycation end products(AGE)in mesangial cells.These MVs could be involved in angiogenesis of microvascular endothelial cells.However,the angiogenic effect of MVs was dismissed in T2DM patients with CAD,while the relevant mechanism remains unclear[17].In a rat model of T2DM with insulin resistance,MVs were able to induce the expression of VCAM-1 and the production of ROS in the cardiac endothelial cells of rats on long term high-fat diet[122].

以下X总表示一个伪BCI-代数，对于X上的犹豫模糊集记[0,1]的幂集为P([0;1]),对于γ∈ P([0,1]), 称⊆为的γ-水平集.

A number of studies have demonstrated that the circulating MVs are elevated in T2DM patients with microvascular complications[123,124]or CVD,including atherosclerosis.Both circulating EMVs and MVs derived from endothelial progenitor cells are elevated in the ischemic stroke models of diabetic db/db mice[125].In T2DM patients with ACS,circulating EMVs positive for CD144 are associated with unstable coronary plaques[126].However,in diabetic patients without typical angina symptoms[15],CD144-positive EMVs are the most significant and sensitive biomarkers as compared to the traditional cardiovascular biomarkers.Many studies have also demonstrated that circulating MVs are involved in pathological progression of diabetic retinopathy with retinal vascular occlusion[16,124],diabetic nepheropathy[127],and diabetic neuropathy[128].

实际上，相似商标的存在，特别是一字之差的商标让行业从业人员头疼不已，这在一定程度上破坏了行业发展的公平性。

Microvesicles and other cardiometabolic diseases

Obesity is another metabolic disorder that is considered as the imbalance between energy intake and expenditure,characteristic with hypertrophy and hyperplasia in adipocytes[129].Our recent work has demonstrated that human macrophages stimulated by TSE may cause the release of MVs with HMGB1[30],and these HMGB1-positive MVs can impair insulin signaling in cultured adipocytes(unpublished work).In line with our findings,Zhang et al.[130]have reported that MVs derived from proinflammatory macrophages may impair insulin signal transduction,particularly the activation of signaling pathways that cause glucose uptake.Furthermore,MVs released from primary adipocytes,which were associated with numerous complicated components,such as leptin,TNF-α,fibroblast growth factor-γ (FGF-γ),MMP-2,and MMP-5,could induce angiogenesis in vivo[131].

The application of left-ventricular assist device(LVAD)in patients with end-stage HF is important for patients who have been waiting for heart transplantation.However,long-term use of LVAD may cause serious stress in endothelial cells,which consequently would lead to the proatherogenic and prothrombotic changes.Ivak et al.[108]has reported that circulating MVs are increased after LVAD implantation in patients with congestive HF.Moreover,significantly higher MV levels have been detected in patients with LVAD implantation who subsequently suffered from adverse events than those detected at the beginning of their LVAD implantation.Nonetheless,Shah et al.[109]have raised doubt about the role of MVs in LVAD pathobiology,as the elevation of PS+microparticle levels may be associated with adverse clinical events.Therefore,they reckon that the use of MVs for predicting LVAD complications may be immature for routine identification of the patients with LVAD implantation.

associated with tumor cell-specific human GAPDH mRNA in xenografted model of human lung cancer.These studies suggest that miRNAs carried in MVs might play an important role in transferring gene regulation functions.

（1）资产出租模式下，学校不用承担酒店经营带来的各种风险和问题，且理论上获得稳定的资产回报，但实际中可能会存在承租人拖欠租金的信用风险。

Microvesicles in therapy of cardiometabolic diseases

Martinez et al.[135]have demonstrated that circulating MVs may be considered as biomarkers to monitor therapeutic efficacy in various cardiometabolic diseases.Cholesterollowering statins have been proved to reduce the levels of circulating MVs derived from leukocytes,platelets,and endothelial cells[136,137].Similarly,other cardioprotective drugs,including angiotensin II receptor blockers[134],calcium blockers[138],aspirin[139],and clopidogrel[140],have also been shown to reduce blood levels of MVs in patients.However,the underlying mechanisms remain to be elucidated.The beneficial effects of these drugs may either result from their direct effects or simply be the consequences of the decreased cholesterol,inflammation,or overall cardiovascular risk.

Microvesicles in regenerative therapies

Initial studies regarding the therapeutic MVs from mesenchymal stem/stromal cells(MSCs)have been reported in animal models of acute kidney failure and MI[141].Increasing evidence[142,143]has demonstrated that exosomes derived from MSCs have cytoprotective effects on pulmonary hypertension induced by hypoxia,alleviate acute lung injury stimulated by endotoxin,and accelerate muscle regeneration in mice.In addition to immune modulation,MSC-MVs are also used in therapeutics by inducing neurogenesis and angiogenesis[144].Chen et al.[145]have reported that MSC-MVs could facilitate miRNA-mediated intercellular communication.Exosomes secreted from GATA-4 overexpressing MSCs are cardioprotective by regulating the expression of anti-apoptotic miRNA in recipient cells[146].In animal model of myocardial ischemia/reperfusion injury,MSC-derived exosomes could prevent adverse remodeling and enhance myocardial viability of the affected mice,through restoring bioenergetics,reducing oxidative stress,and activating pro-survival signaling[147].Therefore,treatment using MSC-derived exosomes may be a potential adjuvant therapy to reperfusion treatment for MI patients.

Extracellular vesicles released from endothelial colony forming cells(ECFCs)can also stimulate neurogenesis and angiogenesis in vitro and in vivo[148,149].ECFC-MVs have been shown to promote revascularization and protect the kidney function in mouse model with ischaemia/reperfusion injury[150].A recent report has suggested that exosomes derived from cardiac progenitor cells could induce transmigration of endothelium and protect myocardial ischemia/reperfusion injury[151].Although further investigations are still needed to optimize the efficacy,the application of stem cellderived vesicles might provide novel insights into cardiovascular regenerative therapy in the future.

Microvesicles in gene therapies

As a potential tool in gene therapy,MVs are able to harbor and transport genetic information to distal target cells.MVs derived from endothelial progenitor cells,which are associated with specific mRNAs,could activate angiogenesis through phosphatidylinositol 3 kinase/protein kinase B signaling pathway[152].Circulating MVs can shuttle numerous specific miRNAs involved in fundamental signal transduction processes of CVD[153].For instance,MVs derived from human THP-1 cells treated by inflammatory factors could harbor miR-150[154],and c-Myb targeted by miR-150 may be involved in endothelial cell migration[155].Furthermore,miR-150 was elevated in EMVs in blood vessels of mice.Similarly,MVs that carry miR-126 play an important role in angiogenesis and vascular integrity[156,157].Notably,application of the miR-126-enriched MVs to ApoE-/-mice could limit the development of aortic plaques of atherosclerosis[158].

Microvesicles as promising therapeutic delivery tools

As we discussed above,MVs that contain RNA,DNA or proteins may be involved in regulation of signaling pathways during pathological processes.Therefore,gene therapy and specific drug delivery may be achieved in the future by inhibiting the formation,release or delivery of MVs.The advantages of applying MVs in therapeutic delivery include decreased toxicity or immunogenicity and increased stability of intracellular environment[159].In addition,some studies have indicated that exosomes could serve as anti-cancer drug delivery vehicles[160].Paclitaxel,an anti-inflammatory drug,has been used to treat MSCs in vitro for stimulating the secretion of exosomes.Interestingly,the paclitaxel-incorporating exosomes have been found to restrain tumor cells from proliferation[161].In addition,exosomes induced by curcumin,a strong inhibitor to tumor cells in the progression of various kinds of cancer,have been demonstrated to block the activation of myeloid cells and subsequently suppress the apoptosis of microglial cells[162,163].Although most of the studies above have been conducted in tumor therapy,MVs as a therapeutic modality might provide promising insights for its application in cardiometabolic diseases in the future,as MVs might have similar protective function in cardiometabolic diseases.

通过革兰氏染色共确定了45株初筛目的菌株，我们对其进行进一步筛选，即复筛。复筛主要分3部分：（1）高效液相色谱法测定MRS培养基中主要有机酸的定性，来初步判断是否是乳酸菌；（2）耐受性验证，要求菌株具有较高的耐受性；（3）45株菌模拟降酸试验，评判标准为该菌株只分解苹果酸、不分解酒石酸，且不产生或微量产生（≤0.6 g/L）醋酸。

Conclusions

Increasing evidence highlights the contribution of MVs to the pathogenesis and progression of cardiometabolic diseases,including atherosclerosis,stroke,CAD,cardiac hypertrophy,and diabetes.MVs could also serve as novel biomarkers for pathologic conditions,including thrombosis,inflammation,endothelial dysfunction,or angiogenesis,in various cardiometabolic diseases.More and more studies also indicate that the molecular characteristics of MVs and their cellular origins could not only reflect the nature of the diseases itself but also be affected by the progress and the treatments,which may provide powerful tools for diagnosis,prognosis,and drug treatment monitoring.However,our understanding on the contributions of MVs to pathophysiological processes of human diseases and their potential mechanisms are still limited,more novel diagnostic or therapeutic approaches and methods involving MVs are expected.In addition,there are still limitations in clinical application of MVs as biomarkers.Firstly,the standardized methods for blood collection and analysis for MVs have not yet been established.It would be better if more sensitive and specific methods could be established,particularly MVs in other body fluids could also be evaluated in the future.Secondly,the underlying mechanisms of cardiometabolic diseases are complicated,which may affect the accuracy of diagnostic and predictive application of MVs in cardiovascular events.Thus,exploration of specific targets would be the focus of the future investigations.Furthermore,most of the published studies had focused on the cell membrane molecules.Interestingly,we have recently found that cytosolic and nuclear molecules can also be carried by MVs[30].Therefore,efforts in further exploring the MV-associated cytosolic and nuclear molecules and their roles in cardiometabolic diseases may also be needed.

In conclusion,studies on the molecular mechanisms underlying the formation and release of MVs,as well as their specific functions in cell–cell communication,may lead to new perspectives and therapeutic strategies for improving the outcome of cardiometabolic diseases.

Competing interests

The authors have declared no competing interests.

This work was supported by the National Natural Science Foundation of China(Grant No.81370422).We thank Professor Kevin Jon Williams for his help to improve this work both in science and language.

References

[1]Wolf P.The nature and significance of platelet products in human plasma.Br J Haematol 1967;13:269–88.

[2]Camussi G,Deregibus MC,Bruno S,Cantaluppi V,Biancone L.Exosomes/microvesicles as a mechanism of cell-to-cell communication.Kidney Int 2010;78:838–48.

[3]Lawson C,Vicencio JM,Yellon DM,Davidson SM.Microvesicles and exosomes:new players in metabolic and cardiovascular disease.J Endocrinol 2016;228:R57–71.

[4]Aurelian SM,Chet¸a DM,Onicescu D.Microvesicles-potential biomarkers for the interrelations atherosclerosis/type 2 diabetes mellitus.Rom J Morphol Embryol 2014;55:1035–9.

[5]Gyorgy B,Modos K,Pallinger E,Paloczi K,Pasztoi M,Misjak P,et al.Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters.Blood 2011;117:e39–48.

[6]Liu ML,Williams KJ.Microvesicles:potential markers and mediators of endothelial dysfunction.Curr Opin Endocrinol Diabetes Obes 2012;19:121–7.

[7]Sluijter JP,Verhage V,Deddens JC,van den Akker F,Doevendans PA.Microvesicles and exosomes for intracardiac communication.Cardiovasc Res 2014;102:302–11.

[8]Chaput N,The´ry C.Exosomes:immune properties and potential clinical implementations.Semin Immunopathol 2011;33:419–40.

[9]Record M,Subra C,Silvente-Poirot S,Poirot M.Exosomes as intercellular signalosomes and pharmacological effectors.Biochem Pharmacol 2011;81:1171–82.

[10]De Hoog VC,Timmers L,Schoneveld AH,Wang JW,van de Weg SM,Sze SK,et al.Serum extracellular vesicle protein levels are associated with acute coronary syndrome.Eur Heart J Acute Cardiovasc Care 2013;2:53–60.

[11]Jeanneteau J,Hibert P,Martinez MC,Tual-Chalot S,Tamareille S,Furber A,et al.Microparticle release in remote ischemic conditioning mechanism.Am J Physiol Heart Circ Physiol 2012;303:H871–7.

[12]Jung C,Sorensson P,Saleh N,Arheden H,Ryde´n L,Pernow J.Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction.Atherosclerosis 2012;221:226–31.

[13]Borges FT,Melo SA,ozdemir BC,Kato N,Revuelta I,Miller CA,et al.TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis.J Am Soc Nephrol 2013;24:385–92.

[14]Sabatier F,Darmon P,Hugel B,Combes V,Sanmarco M,Velut JG,et al.Type 1 and type 2 diabetic patients display different patterns of cellular microparticles.Diabetes 2002;51:2840–5.

[15]Koga H,Sugiyama S,Kugiyama K,Watanabe K,Fukushima H,Tanaka T,et al.Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease.J Am Coll Cardiol 2005;45:1622–30.

[16]Ogata N,Imaizumi M,Nomura S,Shozu A,Arichi M,Matsuoka M,et al.Increased levels of platelet-derived microparticles in patients with diabetic retinopathy.Diabetes Res Clin Pract 2005;68:193–201.

[17]Tsimerman G,Roguin A,Bachar A,Melamed E,Brenner B,Aharon A.Involvement of microparticles in diabetic vascular complications.Thromb Haemost 2011;106:310–21.

[18]Cocucci E,Racchetti G,Meldolesi J.Shedding microvesicles:artefacts no more.Trends Cell Biol 2008;19:43–51.

[19]Liu ML,Williams KJ,Werth VP.Microvesicles in autoimmune diseases.Adv Clin Chem 2016;77:125–75.

[20]Colombo M,Raposo G,Thery C.Biogenesis,secretion,and intercellular interactions of exosomes and other extracellular vesicles.Annu Rev Cell Dev Biol 2014;30:255–89.

[21]Raposo G,Stoorvogel W.Extracellular vesicles:exosomes,microvesicles,and friends.J Cell Biol 2013;200:373–83.

[22]Witwer KW,Buzas EI,Bemis LT,Bora A,Lässer C,Lotvall J,et al.Standardization of sample collection,isolation and analysis methods in extracellular vesicle research.J Extracell Vesicles 2013;27:2.

[23]Wang Y,Chen LM,Liu ML.Microvesicles and diabetic complications–novel mediators,potential biomarkers and therapeutic targets.Acta Pharmacol Sin 2014;35:433–43.

[24]Zwaal RF,Comfurius P,Bevers EM.Surface exposure of phosphatidylserine in pathological cells.Cell Mol Life Sci 2005;62:971–88.

[25]Dasgupta SK,Abdel-Monem H,Niravath P,Le A,Bellera RV,Langlois K,et al.Lactadherin and clearance of platelet-derived microvesicles.Blood 2009;113:1332–9.

[26]Liu ML,Reilly MP,Casasanto P,McKenzie SE,Williams KJ.Cholesterol enrichment of human monocyte/macrophages induces surface exposure of phosphatidylserine and the release of biologically-active tissue factor–positive microvesicles.Arterioscler Thromb Vasc Biol 2007;27:430–5.

[27]Lynch SF,Ludlam CA.Plasma microparticles and vascular disorders.Br J Haematol 2007;137:36–48.

[28]Li M,Yu D,Williams KJ,Liu ML.Tobacco smoke induces the generation of procoagulant microvesicles from human monocytes/macrophages. Arterioscler Thromb Vasc Biol 2010;30:1818–24.

[29]Li CJ,Liu Y,Chen Y,Yu D,Williams KJ,Liu ML.Novel proteolytic microvesicles released from human macrophages after exposure to tobacco smoke.Am J Pathol 2013;182:1552–62.

[30]Chen Y,Li G,Liu Y,Werth VP,Williams KJ,Liu ML.Translocation of endogenous danger signal HMGB1 from nucleus to membrane microvesicles in macrophages.J Cell Physiol 2016;231:2319–26.

[31]Noman MZ,Janji B,Berchem G,Chouaib S.miR-210 and hypoxic microvesicles:two critical components of hypoxia involved in the regulation of killer cells function.Cancer Lett 2016;380:257–62.

[32]Miyazaki Y,Nomura S,Miyake T,Kagawa H,Kitada C,Taniguchi H,et al.High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles.Blood 1996;88:3456–64.

[33]Virgintino D,Rizzi M,Errede M,Strippoli M,Girolamo F,Bertossi M,et al.Plasma membrane-derived microvesicles released from tip endothelial cells during vascular sprouting.Angiogenesis 2012;15:761–9.

[34]Zhou L,Qi XL,Xu MX,Mao Y,Liu ML,Song HM.Microparticles:new light shed on the understanding of venous thromboembolism.Acta Pharmacol Sin 2014;35:1103–10.

[35]Folkesson M,Li C,Frebelius S,Swedenborg J,Wa˚gsäter D,Williams KJ,et al.Proteolytically active ADAM10 and ADAM17 carried on membrane microvesicles in human abdominal aortic aneurysms.Thromb Haemost 2015;114:1165–74.

[36]Mause SF,Weber C.Microparticles:protagonists of a novel communication network for intercellular information exchange.Circ Res 2010;107:1047–57.

[37]Boulanger CM,Tedgui A.Dying for attention:microparticles and angiogenesis.Cardiovasc Res 2005;67:1–3.

[38]Valadi H,Ekstrom K,Bossios A,Sjostrand M,Lee JJ,Lotvall JO.Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.Nat Cell Biol 2007;9:654–9.

[39]Tetta C,Ghigo E,Silengo L,Deregibus MC,Camussi G.Extracellular vesicles as an emerging mechanism of cell-to-cell communication.Endocrine 2013;44:11–9.

[40]Hulsmans M,Holvoet P.MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease.Cardiovasc Res 2013;100:7–18.

[41]Hunter MP,Ismail N,Zhang X,Aguda BD,Lee EJ,Yu L,et al.Detection of microRNA expression in human peripheral blood microvesicles.PLoS One 2008;3:e3694.

[42]Fernandez-Hernando C,Ramirez CM,Goedeke L,Suarez Y.MicroRNAs in metabolic disease.Arterioscler Thromb Vasc Biol 2013;33:178–85.

[43]Hulsmans M,De Keyzer D,Holvoet P.MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis.FASEB J 2011;25:2515–27.

[44]Jansen F,Yang X,Hoelscher M,Cattelan A,Schmitz T,Proebsting S,et al.Endothelial microparticle-mediated transfer of microRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles.Circulation 2013;128:2026–38.

[45]Murakami T,Oakes M,Ogura M,Tovar V,Yamamoto C,Mitsuhashi M.Development of glomerulus-,tubule-,and collecting duct-specific mRNA assay in human urinary exosomes and microvesicles.PLoS One 2014;9:e109074.

[46]Yang J,Wei F,Schafer C,Wong DT.Detection of tumor cellspecific mRNA and protein in exosome-like microvesicles from blood and saliva.PLoS One 2014;9:e110641.

[47]Wallace RG,Twomey LC,Custaud MA,Moyna N,Cummins PM,Mangone M,et al.Potential diagnostic and prognostic biomarkers of epigenetic drift within the cardiovascular compartment.Biomed Res Int 2016;2016:2465763.

[48]Friand V,David G,Zimmermann P.Syntenin and syndecan in the biogenesis of exosomes.Biol Cell 2015;107:331–41.

[49]Morel O,Hugel B,Jesel L,Mallat Z,Lanza F,Douchet MP,et al.Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty.A possible role for GPIIb-IIIa antagonists.J Thromb Haemost 2004;2:1118–26.

[50]Boulanger CM,Scoazec A,Ebrahimian T,Henry P,Mathieu E,Tedgui A,et al.Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction.Circulation 2001;104:2649–52.

[51]Bernal-Mizrachi L,Jy W,Jimenez JJ,Pastor J,Mauro LM,Horstman LL,et al.High levels of circulating endothelial microparticles in patients with acute coronary syndromes.Am Heart J 2003;145:962–70.

[52]Sarlon-Bartoli G,Bennis Y,Lacroix R,Piercecchi-Marti MD,Bartoli MA,Arnaud L,et al.Plasmatic level of leukocytederived microparticles is associated with unstable plaque in asymptomatic patients with high-grade carotid stenosis.J Am Coll Cardiol 2013;62:1436–41.

[53]Del Conde I,Shrimpton CN,Thiagarajan P,Lopez JA.Tissuefactor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005;106:1604–11.

[54]Siljander PR.Platelet-derived microparticles-an updated perspective.Thromb Res 2011;127:S30–3.

[55]Shantsila E,Kamphuisen PW,Lip GY.Circulating microparticles in cardiovascular disease:implications for atherogenesis and atherothrombosis.J Thromb Haemost 2010;8:2358–68.

[56]Wang H,Wang ZH,Kong J,Yang MY,Jiang GH,Wang XP,et al.Oxidized low-density lipoprotein-dependent plateletderived microvesicles trigger procoagulant effects and amplify oxidative stress.Mol Med 2012;18:159–66.

[57]Sinauridze EI,Kireev DA,Popenko NY,Pichugin AV,Panteleev MA,Krymskaya OV,et al.Platelet microparticle membranes have 50-to 100-fold higher specific procoagulant activity than activated platelets.Thromb Haemost 2007;97:425–34.

[58]Nomura S,Shouzu A,Omoto S,Hayakawa T,Kagawa H,Nishikawa M,et al.Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes.Thromb Haemost 1998;80:388–92.

[59]Nomura S,Shouzu A,Omoto S,Nishikawa M,Fukuhara S.Significance of chemokines and activated platelets in patients with diabetes.Clin Exp Immunol 2000;121:437–43.

[60]Werner N,Wassmann S,Ahlers P,Kosiol S,Nickenig G.Circulating CD31+/annexin V+apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease.Arterioscler Thromb Vasc Biol 2006;26:112–6.

[61]Bulut D,Maier K,Bulut-Streich N,Borgel J,Hanefeld C,Mugge A,et al.Circulating endothelial microparticles correlate inversely with endothelial function in patients with ischemic left ventricular dysfunction.J Card Fail 2008;14:336–40.

[62]Esposito K,Ciotola M,Schisano B,Gualdiero R,Sardelli L,Misso L,et al.Endothelial microparticles correlate with endothelial dysfunction in obese women.J Clin Endocrinol Metab 2006;91:3676–9.

[63]Feng B,Chen Y,Luo Y,Chen M,Li X,Ni Y.Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus.Atherosclerosis 2010;208:264–9.

[64]Amabile N,Gue´rin AP,Leroyer A,Mallat Z,Nguyen C,Boddaert J,et al.Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure.J Am Soc Nephrol 2005;16:3381–8.

[65]Schiro A,Wilkinson FL,Weston R,Smyth JV,Serracino-Inglott F,Alexander MY.Endothelial microparticles as conveyors of information in atherosclerotic disease. Atherosclerosis 2014;234:295–302.

[66]Bernal-Mizrachi L,Jy W,Fierro C,Macdonough R,Velazques HA,Purow J,et al.Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes.Int J Cardiol 2004;97:439–46.

[67]Parker B,Al-Husain A,Pemberton P,Yates AP,Ho P,Gorodkin R,et al.Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus.Ann Rheum Dis 2014;73:1144–50.

[68]Wang JG,Williams JC,Davis BK,Jacobson K,Doerschuk CM,Ting JP,et al.Monocytic microparticles activate endothelial cells in an IL-1beta-dependent manner.Blood 2011;118:2366–74.

[69]Rautou PE,Leroyer AS,Ramkhelawon B,Devue C,Duflaut D,Vion AC,et al.Microparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migration. Circ Res 2011;108:335–43.

[70]Mayr M,Grainger D,Mayr U,Leroyer AS,Leseche G,Sidibe A,et al.Proteomics,metabolomics,and immunomics on microparticles derived from human atherosclerotic plaques.Circ Cardiovasc Genet 2009;2:379–88.

[71]Liu ML,Scalia R,Mehta JL,Williams KJ.Cholesterol-induced membrane microvesicles as novel carriers of damage-associated molecular patterns:mechanisms of formation,action,and detoxification.Arterioscler Thromb Vasc Biol 2007;32:2113–21.

[72]Furlan-Freguia C,Marchese P,Gruber A,Ruggeri ZM,Ruf W.P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice.J Clin Invest 2011;121:2932–44.

[73]Allan D,Limbrick AR,Thomas P,Westerman MP.Release of spectrin-free spicules on reoxygenation of sickled erythrocytes.Nature 1982;295:612–3.

[74]Westerman MP,Cole ER,Wu K.The effect of spicules obtained from sickle red cells on clotting activity.Br J Haematol 1984;56:557–62.

[75]Ratajczak MZ,Ratajczak J.Horizontal transfer of RNA and proteins between cells by extracellular microvesicles:14 years later.Clin Transl Med 2016;5:7.

[76]Alix-Panabieres C,Pantel K.Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy.Cancer Discovery 2016;6:479–91.

[77]Brock G,Castellanos-Rizaldos E,Hu L,Coticchia C,Skog J.Liquid biopsy for cancer screening,patient stratification and monitoring.Transl Cancer Res 2015;4:280–90.

[78]Basso C,Calabrese F,Angelini A,Carturan E,Thiene G.Classification and histological,immunohistochemical,and molecular diagnosis of inflammatory myocardial disease.Heart Fail Rev 2013;18:673–81.

[79]Wang Y,Zhang L,Li Y,Chen L,Wang X,Guo W,et al.Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium.Int J Cardiol 2015;192:61–9.

[80]Hansson GK.Inflammation,atherosclerosis,and coronary artery disease.N Engl J Med 2005;352:1685–95.

[81]Williams KJ,Tabas I.The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995;15:551–61.

[82]Lentz BR.Exposure of platelet membrane phosphatidylserine regulates blood coagulation.Prog Lipid Res 2003;42:423–38.

[83]Mobarrez F,Antovic J,Egberg N,Hansson M,Jorneskog G,Hultenby K,et al.A multicolor flow cytometric assay for measurement of platelet-derived microparticles.Thromb Res 2010;125:e110–6.

[84]Sommeijer DW,Joop K,Leyte A,Reitsma PH,Ten CH.Pravastatin reduces fibrinogen receptor GPIIIa on plateletderived microparticles in patients with type 2 diabetes.J Thromb Haemost 2005;3:1168–71.

[85]Raturi A,Miersch S,Hudson JW,Mutus B.Platelet microparticle-associated protein disulfide isomerase promotes platelet aggregation and inactivates insulin.Biochim Biophys Acta 2008;1778:2790–6.

[86]Nomura S.Dynamic role of microparticles in type 2 diabetes mellitus.Curr Diabetes Rev 2009;5:245–51.

[87]Joop K,Berckmans RJ,Nieuwland R,Berkhout J,Romijn FP,Hack CE,et al.Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms.Thromb Haemost 2001;85:810–20.

[88]Daniel L,Fakhouri F,Joly D,Mouthon L,Nusbaum P,Grunfeld JP,et al.Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis.Kidney Int 2006;69:1416–23.

[89]Keuren JF,Magdeleyns EJ,Govers-Riemslag JW,Lindhout T,Curvers J.Effects of storage-induced platelet microparticles on the initiation and propagation phase of blood coagulation.Br J Haematol 2006;134:307–13.

[90]Angelillo-Scherrer A.Leukocyte-derived microparticles in vascular homeostasis.Circ Res 2012;110:356–69.

[91]Suades R,PadroT,Alonso R,Lopez-Miranda J,Mata P,Badimon L.Circulating CD45+/CD3+lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in familial hypercholesterolaemia patients. Thromb Haemost 2014;111:111–21.

[92]Hjuler Nielsen M,Irvine H,Vedel S,Raungaard B,Beck-Nielsen H,Handberg A.Elevated atherosclerosis-related gene expression,monocyte activation and microparticle-release are related to increased lipoprotein-associated oxidative stress in familial hypercholesterolemia.PLoS One 2015;10:e0121516.

[93]Mallat Z,Benamer H,Hugel B,Benessiano J,Steg PG,Freyssinet JM,et al.Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.Circulation 2000;101:841–3.

[94]Chou YI,Kong J,Song R,Yan L,Zheng L,Zhang Y.Correlations of platelet-derived microparticles with thromboxane B2,platelet-activating factor,endothelin-1,and neutrophil to lymphocyte ratio in patients with coronary intermediate lesions.Biomarkers 2014;19:684–92.

[95]Jayachandran M,Litwiller RD,Owen WG,Heit JA,Behrenbeck T,Mulvagh SL,et al.Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women.Am J Physiol Heart Circ Physiol 2008;295:H931–8.

[96]Radecke CE,Warrick AE,Singh GD,Rogers JH,Simon SI,Armstrong EJ.Coronary artery endothelial cells and microparticles increase expression of VCAM-1 in myocardial infarction.Thromb Haemost 2015;113:605–16.

[97]Nomura S,Uehata S,Saito S,Osumi K,Ozeki Y,Kimura Y.Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome.Thromb Haemost 2003;89:506–12.

[98]Mause SF,von Hundelshausen P,Zernecke A,Koenen RR,Weber C.Platelet microparticles:a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium.Arterioscler Thromb Vasc Biol 2005;25:1512–8.

[99]Dignat-George F,Boulanger CM.The many faces of endothelial microparticles.Arterioscler Thromb Vasc Biol 2011;31:27–33.

[100]Curtis AM,Edelberg J,Jonas R,Rogers WT,Moore JS,Syed W,et al.Endothelial microparticles:sophisticated vesicles modulating vascular function.Vasc Med 2013;18:204–14.

[101]Del Turco S,Basta G,Lazzerini G,Evangelista M,Rainaldi G,Tanganelli P,et al.Effect of the administration of n-3 polyunsaturated fatty acids on circulating levels of microparticles in patients with a previous myocardial infarction.Haematologica 2008;93:892–9.

[102]Katz SD,Hryniewicz K,Hriljac I,Balidemaj K,Dimayuga C,Hudaihed A,et al.Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure.Circulation 2005;111:310–4.

[103]Chong AY,Blann AD,Patel J,Freestone B,Hughes E,Lip GY.Endothelial dysfunction and damage in congestive heart failure:relation of flow-mediated dilation to circulating endothelial cells,plasma indexes of endothelial damage,and brain natriuretic peptide.Circulation 2004;110:1794–8.

[104]Nozaki T,Sugiyama S,Sugamura K,Ohba K,Matsuzawa Y,Konishi M,et al.Prognostic value of endothelial microparticles in patients with heart failure.Eur J Heart Fail 2010;12:1223–8.

[105]Walenta K,Schwarz V,Schirmer SH,Kindermann I,Friedrich EB,Solomayer EF,et al.Circulating microparticles as indicators of peripartum cardiomyopathy.Eur Heart J 2012;33:1469–79.

[106]Kumpers P,Erdbrugger U,Grossheim M,Meyer GP,Hiss M,Gwinner W,et al.Endothelial microparticles as a diagnostic aid in Churg-Strauss vasculitis-induced cardiomyopathy.Clin Exp Rheumatol 2008;26:S86–9.

[107]Bulut D,Scheeler M,Niedballa LM,Miebach T,Mugge A.Effects of immunoadsorption on endothelial function,circulating endothelial progenitor cells and circulating microparticles in patients with inflammatory dilated cardiomyopathy.Clin Res Cardiol 2011;100:603–10.

[108]Ivak P,Pitha J,Wohlfahrt P,Kralova Lesna I,Stavek P,Dorazilova Z,et al.Endothelial dysfunction expressed as endothelial microparticles in patients with end-stage heart failure.Physiol Res 2014;63:S369–73.

[109]Shah KB,Kontos MC.Microparticles and left ventricular assist device complications:a causal association?J Heart Lung Transplant 2014;33:468–9.

[110]Zhang YN,VernooijF,Ibrahim I,OoiS,GijsbertsCM,Schoneveld AH,et al.Extracellular vesicle proteins associated with systemic vascular events correlate with heart failure:an observational study in a dyspnoea cohort.PLoS One 2016;11:e0148073.

[111]Alkhatatbeh MJ,Enjeti AK,Acharya S,Thorne RF,Lincz LF.The origin of circulating CD36 in type 2 diabetes.Nutr Diabetes 2013;3:e59.

[112]Morel O,Jesel L,Freyssinet JM,Toti F.Elevated levels of procoagulant microparticles in a patient with myocardial infarction,antiphospholipid antibodies and multifocal cardiac thrombosis.Thromb J 2005;3:15.

[113]Barnett A.DPP-4 inhibitors and their potential role in the management of type 2 diabetes.Int J Clin Pract 2006;60:1454–70.

[114]Sun AL,Deng JT,Guan GJ,Chen SH,Liu YT,Cheng J,et al.Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease.Diab Vasc Dis Res 2012;9:301–8.

[115]Pisitkun T,Shen RF,Knepper MA.Identification and proteomic profiling of exosomes in human urine.Proc Natl Acad Sci USA 2004;101:13368–73.

[116]Pala L,Mannucci E,Pezzatini A,Ciani S,Sardi J,Raimondi L,et al.Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells.Biochem Biophys Res Commun 2003;310:28–31.

[117]Cohen Z,Gonzales RF,Davis-Gorman GF,Copeland JG,McDonagh PF.Thrombin activity and platelet microparticle formation are increased in type 2 diabetic platelets:a potential correlation with caspase activation. Thromb Res 2002;107:217–21.

[118]Cimmino G,D’Amico C,Vaccaro V,D’Anna M,Golino P.The missing link between atherosclerosis,inflammation and thrombosis:is it tissue factor.Expert Rev Cardiovasc Ther 2011;9:517–23.

[119]Jansen F,Yang X,Franklin BS,Hoelscher M,Schmitz T,Bedorf J,et al.High glucose condition increases NADPH oxidase activity in endothelial microparticles that promote vascular inflammation.Cardiovasc Res 2013;98:94–106.

[120]Puddu P,Puddu GM,Cravero E,Muscari S,Muscari A.The involvement of circulating microparticles in inflammation,coagulation and cardiovascular diseases.Can J Cardiol 2010;26:140–5.

[121]Ettelaie C,Su S,Li C,Collier ME.Tissue factor-containing microparticles released from mesangial cells in response to high glucose and AGE induce tube formation in microvascular cells.Microvasc Res 2008;76:152–60.

[122]Heinrich LF,Andersen DK,Cleasby ME,Lawson C.Long-term high fat feeding of rats results in increased numbers of circulating microvesicles with pro-inflammatory effects on endothelial cells.Br J Nutr 2015;113:1704–11.

[123]Omoto S,Nomura S,Shouzu A,Hayakawa T,Shimizu H,Miyake Y,et al.Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy.Nephron 1999;81:271–7.

[124]Ogata N,Nomura S,Shouzu A,Imaizumi M,Arichi M,Matsumura M.Elevation of monocyte-derived microparticles in patients with diabetic retinopathy.Diabetes Res Clin Pract 2006;73:241–8.

[125]Chen J,Chen S,Chen Y,Zhang C,Wang J,Zhang W,et al.Circulating endothelial progenitor cells and cellular membrane microparticles in db/db diabetic mouse:possible implications in cerebral ischemic damage.Am J Physiol Endocrinol Metab 2011;301:E62–71.

[126]Bernard S,Loffroy R,Serusclat A,Boussel L,Bonnefoy E,Thevenon C,et al.Increased levels of endothelial microparticles CD144(VE-cadherin)positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by multidetector computed tomography(MDCT).Atherosclerosis 2009;203:429–35.

[127]Kobayashi S,Satoh M,Namikoshi T,Haruna Y,Fujimoto S,Arakawa S,et al.Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocininduced diabetic nephropathy. Clin Exp Nephrol 2008;12:119–25.

[128]Omoto S,Nomura S,Shouzu A,Nishikawa M,Fukuhara S,Iwasaka T.Detection of monocyte-derived microparticles in patients with type II diabetes mellitus. Diabetologia 2002;45:550–5.

[129]Muller G.Microvesicles/exosomes as potential novel biomarkers ofmetabolic diseases.Diabetes Metab Syndr Obes 2012;5:247–82.

[130]Zhang Y,Shi L,Mei H,Zhang J,Zhu Y,Han X,et al.Inflamed macrophage microvesicles induce insulin resistance in human adipocytes.Nutr Metab(Lond)2015;12:21.

[131]Aoki N,Yokoyama R,Asai N,Ohki M,Ohki Y,Kusubata K,et al.Adipocyte-derived microvesicles are associated with multiple angiogenic factors and induce angiogenesis in vivo and in vitro.Endocrinology 2010;151:2567–76.

[132]Preston RA,Jy W,Jimenez JJ,Mauro LM,Horstman LL,Valle M,et al.Effects of severe hypertension on endothelial and platelet microparticles.Hypertension 2003;41:211–7.

[133]Cordazzo C,Neri T,Petrini S,Lombardi S,Balı`a C,Cianchetti S,et al.Angiotensin II induces the generation of procoagulant microparticles by human mononuclear cells via an angiotensin type 2 receptor-mediated pathway.Thromb Res 2013;131:e168–74.

[134]Hsu CY,Huang PH,Chiang CH,Leu HB,Huang CC,Chen JW,et al.Increased circulating endothelial apoptotic microparticle to endothelial progenitor cell ratio is associated with subsequent decline in glomerular filtration rate in hypertensive patients.PLoS One 2013;8:e68644.

[135]Martinez MC,Tual-Chalot S,Leonetti D,Andriantsitohaina R.Microparticles:targets and tools in cardiovascular disease.Trends Pharmacol Sci 2011;32:659–65.

[136]Suades R,PadroT,Alonso R,Mata P,Badimon L.Lipidlowering therapy with statins reduces microparticle shedding from endothelium,platelets and inflammatory cells.Thromb Haemost 2013;110:366–77.

[137]Nomura S,Shouzu A,Omoto S,Nishikawa M,Iwasaka T.Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus.Clin Appl Thromb Hemost 2004;10:133–41.

[138]Labios M,Martinez M,Gabriel F,Guiral V,Munoz A,Aznar J.Effect of eprosartan on cytoplasmic free calcium mobilization,platelet activation,and microparticle formation in hypertension.Am J Hypertens 2004;17:757–63.

[139]Bulut D,Becker V,Mugge A.Acetylsalicylate reduces endothelial and platelet derived microparticles in patients with coronary artery disease.Can J Physiol Pharmacol 2011;89:239–44.

[140]Franc¸a CN,Pinheiro LF,Izar MC,Brunialti MK,Saloma˜o R,Bianco HT,et al.Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease.Circ J 2012;76:729–36.

[141]Bruno S,Grange C,Deregibus MC,Calogero RA,Saviozzi S,Collino F,et al.Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.J Am Soc Nephrol 2009;20:1053–67.

[142]Lee C,Mitsialis SA,Aslam M,Vitali SH,Vergadi E,Konstantinou G,et al.Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension.Circulation 2012;126:2601–11.

[143]Nakamura Y,Miyaki S,Ishitobi H,Matsuyama S,Nakasa T,Kamei N,et al.Mesenchymal-stem-cell-derived exosomes accelerate skeletal muscle regeneration.FEBS Lett 2015;589:1257–65.

[144]Hsieh JY,Wang HW,Chang SJ,Liao KH,Lee IH,Lin WS,et al.Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection,neurogenesis,and angiogenesis.PLoS One 2013;8:e72604.

[145]Chen TS,Lai RC,Lee MM,Choo AB,Lee CN,Lim SK.Mesenchymal stem cell secretes microparticles enriched in premicroRNAs.Nucl Acids Res 2010;38:215–24.

[146]Yu B,Kim HW,Gong M,Wang J,Millard RW,Wang Y,et al.Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection.Int J Cardiol 2015;182:349–60.

[147]Arslan F,Lai RC,Smeets MB,Akeroyd L,Choo A,Aguor EN,et al.Mesenchymal stem cell-derived exosomes increase ATP levels,decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury.Stem Cell Res 2013;10:301–12.

[148]Zhang B,Wu X,Zhang X,Sun Y,Yan Y,Shi H,et al.Human umbilical cord mesenchymal stem cell exosomes enhance angiogenesis through the Wnt4/beta-catenin pathway.Stem Cells Transl Med 2015;4:513–22.

[149]Bian S,Zhang L,Duan L,Wang X,Min Y,Yu H.Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model.J Mol Med 2014;92:387–97.

[150]Ranghino A,Cantaluppi V,Grange C,Vitillo L,Fop F,Biancone L,et al.Endothelial progenitor cell-derived microvesicles improve neovascularization in a murine model of hindlimb ischemia.Int J Immunopathol Pharmacol 2012;25:75–85.

[151]Vrijsen KR,Sluijter JP,Schuchardt MW,Van Balkom BW,Noort WA,Chamuleau SA,et al.Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells.J Cell Mol Med 2010;14:1064–70.

[152]Deregibus MC,Cantaluppi V,Calogero R,LoIacono M,Tetta C,Biancone L,et al.Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA.Blood 2007;110:2440–8.

[153]Diehl P,Fricke A,Sander L,Stamm J,Bassler N,Htun N,et al.Microparticles:major transport vehicles for distinct microRNAs in circulation.Cardiovasc Res 2012;93:633–44.

[154]Zhang Y,Liu D,Chen X,Li J,Li L,Bian Z,et al.Secreted monocytic miR-150 enhances targeted endothelial cell migration.Mol Cell 2010;39:133–44.

[155]Akao Y,Iio A,Itoh T,Noguchi S,Itoh Y,Ohtsuki Y,et al.Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages.Mol Ther 2011;19:395–9.

[156]Fish JE,Santoro MM,Morton SU,Yu S,Yeh RF,Wythe JD,et al.miR-126 regulates angiogenic signaling and vascular integrity.Dev Cell 2008;15:272–84.

[157]Wang S,Aurora AB,Johnson BA,Qi X,Mcanally J,Hill JA,et al.The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis.Dev Cell 2008;15:261–71.

[158]Zernecke A,Bidzhekov K,Noels H,Shagdarsuren E,Gan L,Denecke B,et al.Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection.Sci Signal 2009;2:81.

[159]El Andaloussi S,Maeger I,Breakefield XO,Wood MJ.Extracellular vesicles:biology and emerging therapeutic opportunities.Nat Rev Drug Discov 2013;12:347–57.

[160]Johnsen KB,Gudbergsson JM,Skov MN,Pilgaard L,Moos T,Duroux M.A comprehensive overview of exosomes as drug delivery vehicles–endogenous nanocarriers for targeted cancer therapy.Biochim Biophys Acta 2014;1846:75–87.

[161]Pascucci L,Cocce V,Bonomi A,Ami D,Ceccarelli P,Ciusani E,et al.Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth:a new approach for drug delivery. J Control Release 2014;192:262–70.

[162]Sun D,Zhuang X,Xiang X,Liu Y,Zhang S,Liu C,et al.A novel nanoparticle drug delivery system:the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes.Mol Ther 2010;18:1606–14.

[163]Zhuang X,Xiang X,Grizzle W,Sun D,Zhang S,Axtell RC,et al.Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain.Mol Ther 2011;19:1769–79.